Tomoyuki Sugimoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tomoyuki Sugimoto has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Scott R. Evans
The Biostatistics Center, Milken Institute School of Public Health, The George Washington University
4 shared publications - Toshimitsu Hamasaki
The Biostatistics Center, Milken Institute School of Public Health, The George Washington University
4 shared publications - Takashi Sozu
Department of Information and Computer Technology, Faculty of Engineering, Tokyo University of Science, Tokyo, Japan
3 shared publications - Chieko Matsui
Teijin Institute for Bio-medical Research, Teijin Pharma Ltd., Tokyo 191-8512, Japan
1 shared publication Hideki Mochizuki
Osaka Univ, Grad Sch Med, Dept Neurol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan
1 shared publicationHisashi Murata
Osaka Univ, Grad Sch Med, Dept Neurol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan
1 shared publication
Latest Publications
- 16 October 2024
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 24 (11) , 1246-1248
A blind spot in cognitive evaluation for risk of falls in older patients in rehabilitation wards: A nested case–control study
- 16 October 2024
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 24 (11) , 1246-1248
A blind spot in cognitive evaluation for risk of falls in older patients in rehabilitation wards: A nested case–control study
- Open Access
- 15 June 2024
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 243, 108378
Switching disease-modifying therapies from sphingosine-1-phosphate receptor modulators to natalizumab or dimethyl fumarate restores immune responses after SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis
- 15 June 2024
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 243, 108378
Open AccessSwitching disease-modifying therapies from sphingosine-1-phosphate receptor modulators to natalizumab or dimethyl fumarate restores immune responses after SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis
- Open Access
- 18 April 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (4) , 490
Elevated Serum Xanthine Oxidase and Its Correlation with Antioxidant Status in Patients with Parkinson’s Disease
Parkinson’s disease (PD) is a neurodegenerative movement disorder associated with a loss of dopamine neurons in the substantia nigra. The diagnosis of PD is sensitive since it shows clinical features that are common with other neurodegenerative diseases. In addition, most symptoms arise at the late stage of the disease, where most dopaminergic neurons are already damaged. Several studies reported that oxidative stress is a key modulator in the development of PD. This condition occurs due to excess reactive oxygen species (ROS) production in the cellular system and the incapability of antioxidants to neutralize it. In this study, we focused on the pathology of PD by measuring serum xanthine oxidase (XO) activity, which is an enzyme that generates ROS. Interestingly, the serum XO activity of patients with PD was markedly upregulated compared to patients with other neurological diseases (ONDs) as a control. Moreover, serum XO activity in patients with PD showed a significant correlation with the disease severity based on the Hoehn and Yahr (HY) stages. The investigation of antioxidant status also revealed that serum uric acid levels were significantly lower in the severe group (HY ≥ 3) than in the ONDs group. Together, these results suggest that XO activity may contribute to the development of PD and might potentially be a biomarker for determining disease severity in patients with PD.
- 18 April 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (4) , 490
Open AccessElevated Serum Xanthine Oxidase and Its Correlation with Antioxidant Status in Patients with Parkinson’s Disease
Parkinson’s disease (PD) is a neurodegenerative movement disorder associated with a loss of dopamine neurons in the substantia nigra. The diagnosis of PD is sensitive since it shows clinical features that are common with other neurodegenerative diseases. In addition, most symptoms arise at the late stage of the disease, where most dopaminergic neurons are already damaged. Several studies reported that oxidative stress is a key modulator in the development of PD. This condition occurs due to excess reactive oxygen species (ROS) production in the cellular system and the incapability of antioxidants to neutralize it. In this study, we focused on the pathology of PD by measuring serum xanthine oxidase (XO) activity, which is an enzyme that generates ROS. Interestingly, the serum XO activity of patients with PD was markedly upregulated compared to patients with other neurological diseases (ONDs) as a control. Moreover, serum XO activity in patients with PD showed a significant correlation with the disease severity based on the Hoehn and Yahr (HY) stages. The investigation of antioxidant status also revealed that serum uric acid levels were significantly lower in the severe group (HY ≥ 3) than in the ONDs group. Together, these results suggest that XO activity may contribute to the development of PD and might potentially be a biomarker for determining disease severity in patients with PD.
- 26 July 2022
- Published by Springer Nature in Annals of the Institute of Statistical Mathematics
- Vol. 75 (2) , 1-22
Inference using an exact distribution of test statistic for random-effects meta-analysis
- 26 July 2022
- Published by Springer Nature in Annals of the Institute of Statistical Mathematics
- Vol. 75 (2) , 1-22
Inference using an exact distribution of test statistic for random-effects meta-analysis
- 12 April 2019
- Published by Springer Nature in Lifetime Data Analysis
- Vol. 26 (2) , 266-291
Group-sequential logrank methods for trial designs using bivariate non-competing event-time outcomes
We discuss the multivariate (2L-variate) correlation structure and the asymptotic distribution for the group-sequential weighted logrank statistics formulated when monitoring two correlated event-time outcomes in clinical trials. The asymptotic distribution and the variance–covariance for the 2L-variate weighted logrank statistic are derived as available in various group-sequential trial designs. These methods are used to determine a group-sequential testing procedure based on calendar times or information fractions. We apply the theoretical results to a group-sequential method for monitoring a clinical trial with early stopping for efficacy when the trial is designed to evaluate the joint effect on two correlated event-time outcomes. We illustrate the method with application to a clinical trial and describe how to calculate the required sample sizes and numbers of events.
- 12 April 2019
- Published by Springer Nature in Lifetime Data Analysis
- Vol. 26 (2) , 266-291
Group-sequential logrank methods for trial designs using bivariate non-competing event-time outcomes
We discuss the multivariate (2L-variate) correlation structure and the asymptotic distribution for the group-sequential weighted logrank statistics formulated when monitoring two correlated event-time outcomes in clinical trials. The asymptotic distribution and the variance–covariance for the 2L-variate weighted logrank statistic are derived as available in various group-sequential trial designs. These methods are used to determine a group-sequential testing procedure based on calendar times or information fractions. We apply the theoretical results to a group-sequential method for monitoring a clinical trial with early stopping for efficacy when the trial is designed to evaluate the joint effect on two correlated event-time outcomes. We illustrate the method with application to a clinical trial and describe how to calculate the required sample sizes and numbers of events.
- 21 August 2015
- Published by Springer Nature
- p. 41-58
Convenient Sample Size Formula
- 21 August 2015
- Published by Springer Nature
- p. 25-39
Binary Co-primary Endpoints
- 21 August 2015
- Published by Springer Nature
- p. 7-23
Continuous Co-primary Endpoints